Back

Left atrial size-based anticoagulation discontinuation after catheter ablation for atrial fibrillation: a post-hoc analysis of the ALONE-AF Trial

14 April 2026 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation and stroke Oral Anticoagulation EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Daehoon Kim

Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul (Korea (Republic of))

6 More presentations in this session

Presentation thumbnail
Risk of early device-related thrombosis in post-Watchman cases on low-dose oral-anticoagulation versus dual-antiplatelet therapy
Doctor S. Mohanty (Austin, US)
Abstract Slides Video
Presentation thumbnail
Procedural and clinical outcomes after left atrial appendage occlusion in patients with preprocedural sludge or thrombus: a single-center experience
Doctor H. Alessandrini (Luebeck, DE)
Abstract Slides Video
Presentation thumbnail
From prescription to outcome: real-world utilization of direct oral anticoagulants in atrial fibrillation across Europe
Doctor R. Salguero-Bodes (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Left atrial appendage occlusion with prior thrombus under OAC: feasibility and safety in a case series of patients with LA dilation and impaired atrial function
Miss F. Beisegel (Berlin, DE) Doctor D. Schoeppenthau (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Long-term efficacy and safety of left atrial appendage closure with WATCHMAN in Japanese nonvalvular atrial fibrillation patients
Doctor M. Nakano (Chiba, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation and stroke

The Event

Event poster

EHRA 2026

14 April 2026 12:30 CET
You may be interested in
thumbnail
Congress Presentation
ALONE-AF: Discontinuing long-Term oral anticoagulation after successful atrial fibrillation ablation
thumbnail
Congress Presentation
CHA2DS2-VASc score-based anticoagulation management after catheter ablation for atrial fibrillation: a post-hoc analysis of the ALONE-AF trial
thumbnail
Congress Presentation
Can we stop anticoagulation following 'successful' atrial fibrillation ablation?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources